Guidant expects 45% sales growth in the third quarter for its implantable cardiac defibrillators. The device manufacturer looks to increase its market share, chipping away at Medtronic's market dominance.
Published in Brief:
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore